

AMENDMENT TO THE SPECIFICATION:

Please amend the specification as follows. On page 8, line 25 to page 9, line 4, please amend the paragraph as follows:

Thus, the “5-HT_{2B} receptor antagonistic compound having a selective binding affinity to the 5-HT_{2B} receptor (hereinafter abbreviated to 5-HT_{2B} selective antagonistic compound)” includes specifically those selective against α_1 , M₁ and D₂ receptors, preferably against α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT₃, 5-HT₄, 5-HT₆ and 5-HT₇ receptors, more preferably against α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄, 5-HT₆ and 5-HT₇ receptors.